5285W-12: Ziopharm E-NSCLC

CRC 12046: A Randomized Study of Palifosfamide-tris in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy vs Carboplatin and Etoposide (CE) Alone in Chemotherapy Naive Patients with Extensive-Stage Small Cell Lung Cancer

Type of Study
Cancer (Oncology) - Lung
Location
Swedish Cancer Institute
Short Description

Purpose: This is a multinational, multicenter, randomized controlled, open-label, adaptive study to evaluate the efficacy of PaCE chemotherapy in chemotherapy naive subjects with extensive-stage SCLC

Status
Temporarily Closed
Principal Investigator
Howard (Jack) West, M.D.
Eligibility Notes
  • Documented extensive-stage small cell lung cancer
  • Patient has received no prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer
  • ECOG Performance Status of 0, 1 or 2
  • No previously untreated (non-irradiated), symptomatic brain metastases
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Phone
(206) 215-3086
Email
CancerResearch@swedish.org